Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

Lopci, E; Aide, N; Dimitrakopoulou-Strauss, A; Dercle, L; Iravani, A; Seban, RD; Sachpekidis, C; Humbert, O; Gheysens, O; Glaudemans, AWJM; Weber, WA; Van den Abbeele, AD; Wahl, RL; Scott, Andrew; Pandit-Taskar, N; Hicks, RJ

doi:10.26181/23544216.v1

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

journal contribution

posted on 2023-06-20, 05:47 authored by E Lopci, N Aide, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, RD Seban, C Sachpekidis, O Humbert, O Gheysens, AWJM Glaudemans, WA Weber, AD Van den Abbeele, RL Wahl, Andrew ScottAndrew Scott, N Pandit-Taskar, RJ Hicks

Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published “Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0”. These recommendations arose from a fruitful collaboration between international nuclear medicine societies and experts in cancer treatment. In this perspective, the key elements of the initiative are reported, summarizing the core aspects of the guidelines for radiologists and nuclear medicine physicians. Beyond the previous guidelines, this perspective adds further commentary on how this technology can advance development of novel therapeutic approaches and guide management of individual patients.

History

Publication Date

2022-12-20

Journal

Cancer Imaging

Volume

22

Article Number

73

Pagination

5p.

Publisher

Springer Nature

ISSN

1470-7330

Rights Statement

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.